Results 241 to 250 of about 20,264 (293)

Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy. [PDF]

CPT Pharmacometrics Syst Pharmacol
Salem F, Nguyen D, Bush M, Moore KP, Mudunuru J, Stamatopoulos K, Thakkar N, Taskar KS.   +7 more
europepmc   +1 more source

Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis. [PDF]

Antimicrob Agents Chemother
Vallée M, Aranzana-Climent V, Moreau J, Lamarche I, Fontanier T, Barc C, Kasal-Hoc N, Debiais-Delpech C, Mirfendereski H, Pezant J, Pinard A, Clarhaut J, Couet W, Cazenave-Roblot F, Marchand S.   +14 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles

Nano Letters, 2016
A physiologically based pharmacokinetic model was developed for accurately characterizing and predicting the in vivo fate of long-circulating inorganic nanoparticles (NPs).
Xiaowen Liang, Haolu Wang, Jeffrey E Grice   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles

Journal of Nanoscience and Nanotechnology, 2010
The worldwide commerce involving nanoparticles will soon reach $1 trillion and already we have more than 600 commercial products containing nanoparticles. Because nanoparticles are invisible and little is known about their toxicities, there has been concern about health effects in humans.
Raymond S H, Yang, Louis W, Chang, Chung Shi, Yang, Pinpin, Lin   +3 more
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling of Nanoparticles

ACS Nano, 2010
Rapid expansion of nanoparticle research demands new technologies that will enable better interpretation of experimental data and assistance in the rational design of future nanoparticles. The use of physiologically based pharmacokinetic (PBPK) models may serve as powerful tools to meet these needs.
Li, Mingguang, Al-Jamal, Khuloud T, Kostarelos, Kostas, Reineke, Joshua   +3 more
openaire   +3 more sources

Physiologically-based pharmacokinetic simulation modelling

Advanced Drug Delivery Reviews, 2002
Drug selection is now widely viewed as an important and relatively new, yet largely unsolved, bottleneck in the drug discovery and development process. In order to achieve an efficient selection process, high quality, rapid, predictive and correlative ADME models are required in order for them to be confidently used to support critical financial ...
George M, Grass, Patrick J, Sinko
openaire   +2 more sources

Innovations and Improvements in Pharmacokinetic Models Based on Physiology

Current Drug Delivery, 2017
Background: Accompanied by significant improvements of modeling techniques and computational methods in medical sciences, the last thirty years saw the flourishing of pharmacokinetic models for applications in the pharmacometric field. In particular, physiologically based pharmacokinetic (PBPK) models, grounded
ABBIATI, ROBERTO ANDREA, MANCA, DAVIDE
openaire   +2 more sources

Definition and validation of a patient-individualized physiologically-based pharmacokinetic model [PDF]

Computers and Chemical Engineering, 2016
Pharmacokinetic modeling based on a mechanistic approach is a promising tool for drug concentration prediction in living beings. The development of a reduced physiologically-based pharmacokinetic model (PBPK model), is performed by lumping organs and ...
Roberto Andrea Abbiati, Gaetano Lamberti, Mario Grassi   +2 more
exaly   +2 more sources

Physiologically Based Pharmacokinetic/Toxicokinetic Modeling

2012
Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the ...
Jerry L, Campbell, Rebecca A, Clewell, P Robinan, Gentry, Melvin E, Andersen, Harvey J, Clewell   +4 more
openaire   +2 more sources

Physiologically based pharmacokinetic model for topotecan in mice

Journal of Pharmacokinetics and Pharmacodynamics, 2010
Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer. In this article, we have developed a physiologically based pharmacokinetic model to characterize and predict topotecan concentrations in mouse plasma and tissues. Single intravenous (IV) doses (5, 10 and 30 mg/kg) of topotecan were administered to
Dhaval K, Shah, Joseph P, Balthasar
openaire   +2 more sources